Braveheart Bio, Inc.（BRVE）资讯与事件BRVEBraveheart Bio, Inc.

Several Companies Successfully Debut, BlossomHill Therapeutics Opens at $16.08

Several companies made their market debuts in the past week, highlighted by strong demand for new biopharma listings and a rare secondary only bank offering that drew attention for its structure.LATEST IPOS AND DIRECT LISTINGS:BlossomHill Therapeuticsopened on August 7 at $15.75. The company priced 9.375M shares at $16.00. The deal size was increased to 9.375M shares of common stock from 7.8M shares of common stock and priced within the $15.00-$17.00 range. BlossomHill Therapeutics is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer.Latigo Biotherapeuticsopened on August 7 at $21. The clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines priced 19.2M shares at $18.00. The deal size was increased to 19.2M shares of common stock from 16M shares of common stock and priced at the high-end of the $16.00-$18.00 range.Ticketplusopened on August 7 at $7. The company priced 1.875M shares at $8.00. The deal priced at the low end of its $8.00-$10.00 range. Ticketplus is a technology company that operates a proprietary, full-stack technology platform powering live entertainment across Latin America.Braveheart Bioopened on August 6 at $30.20. The clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases priced 21.25M shares at $18.00. The deal size was increased to 21.25M shares of common stock from 18.75M shares and priced above the $15.00-$17.00 range.River City Bankopened on August 6 at $45. The company priced its initial public offering of 2.7M shares of its common stock at a public offering price of $45.00 per share. The offering consists solely of existing shares held by two of the bank's longtime shareholders associated with the family of the bank's founder, Jon Kelly. As a result, the IPO is structured as a 100% secondary offering, with no new shares issued by the bank, River City noted. As of June 30, River City Bank had approximately $6.0B in assets, $4.7B in gross loans, and $5.4B in deposits.Attoviaopened on August 5 at $21.00. The company priced 17M shares at $17.00. The deal size was increased to 17M shares of common stock from 12.5M shares. The deal priced at the top of the $15.00-$17.00 range. All shares of common stock to be sold in the offering will be sold by Attovia. Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.RECENT SPAC IPOS:Pinnacle Acquisitionopened on August 7 at $9.97. Santander and CIBC Capital Markets are acting as joint book-running managers.TCGX Acquisitionopened on August 5 at $10.30. While the company may pursue an acquisition opportunity in any business, industry, sector or geographical location, it intends to focus its search on the healthcare and healthcare-related industries, particularly in the life sciences and medical technology sectors.PERFORMANCE:Prices as of 10:45 am ET on Monday, August 10 -BlossomHill Therapeutics – fractionally up at $16.08;Latigo Biotherapeutics – up over 1% at $18.47;Ticketplus – up more than 2% at $7.17;Braveheart Bio – fractionally up at $30.11;River City Bank – fractionally down at $46.76;Attovia – down almost 6% at $19.04;RECENT IPOS TO WATCH:Standard Nuclearand Csquareare already seeing coverage roll out, while QumulusAIis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include EvoAirand Inspire Brands.Clickto see upcoming IPO calendar on TipRanks.EvoAir Holdingshas filed for a firm commitment initial public offering of shares of common stock and anticipates that the initial public offering price of shares will be between $4.00 and $5.00 per share. The company said it will apply to list its common stock on the Nasdaq Capital Market under the symbol "EVOH". EvoAir Group is an emerging green technology focusing on eco-friendly heating, ventilation, air conditioning inventions and efforts in the environmental, social and governance initiatives. The Group is principally engaged in the research and development, manufacturing, sale and marketing of HVAC products for residential, commercial and industrial uses.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.

Braveheart Bio Prices 21.25M Shares at $18.00

Braveheart Bio - a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases - priced 21.25M shares at $18.00. The deal size was increased to 21.25M shares of common stock from 18.75M shares and priced above the $15.00-$17.00 range.

Braveheart Bio Prices 21.25M Shares at $18.00

Braveheart Bio priced 21.25M shares at $18.00. The deal size was increased to 21.25M shares of common stock from 18.75M shares and priced above the $15.00-$17.00 range. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor Fitzgerald acted as joint book running managers for the offering. Braveheart Bio is a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases.